Tada Yuji, O-Wang Jiyang, Seimiya Mika, Takiguchi Yuichi, Tatsumi Koichiro, Kuriyama Takayuki, Tagawa Masatoshi
Division of Pathology, Chiba Cancer Center Research Institute, Japan.
Anticancer Res. 2002 Mar-Apr;22(2A):831-6.
Interaction of Fas and Fas ligand (FasL) in immunocompetent cells plays a crucial role(s) in their effector functions and in the regulation of host immune responses. Expression of FasL in tumors possibly counteracts Fas-positive effector T cells that infiltrate into tumors and consequently the Fas/FasL interaction can contribute to the escape of tumor cells from systemic immune systems. However, forced expression of FasL in tumors unexpectedly induced migration of neutrophils into the tumors and the FasL-expressing tumors were rejected due to the inflammatory reaction. Since FasL is released from the cell surface, we examined whether soluble or membrane-bound FdsL molecules produced such antitumor effects. Fas-positive B cells were effectively killed by membrane-bound but not soluble FasL in which the leader sequence of interleukin-4 was ligated with the extracytoplasmic portion of FasL. Mice inoculated with A11 murine lung cancer cells expressing membrane-bound FasL did not develop tumors and had few spontaneous lung metastatic foci. In contrast, mice injected with A11 cells secreting soluble FasL developed tumors; the growth of the tumors and the number of lung metastatic foci from subcutaneous tumors were not different from those of parent tumors. The chemotactic activity of FasL, tested by intraperitoneal injection of parent and the FasL-expressing A11 cells, showed that the level of neutrophil migration by A11 cells secreting soluble FasL was greater than that by parent cells but was not as significant as that by A11 cells expressing membrane-bound FasL. The antitumor activity induced by expressed FasL seems to be correlated with the apoptosis-inducing activity through the Fas/FasL interaction but not directly with the chemotactic activity for neutrophils.
免疫活性细胞中Fas与Fas配体(FasL)的相互作用在其效应功能及宿主免疫反应调节中发挥着关键作用。肿瘤中FasL的表达可能会对抗浸润到肿瘤中的Fas阳性效应T细胞,因此Fas/FasL相互作用可能有助于肿瘤细胞逃避免疫系统。然而,肿瘤中FasL的强制表达意外地诱导了中性粒细胞向肿瘤迁移,且表达FasL的肿瘤因炎症反应而被排斥。由于FasL从细胞表面释放,我们研究了可溶性或膜结合的FdsL分子是否产生这种抗肿瘤作用。Fas阳性B细胞可被膜结合而非可溶性FasL有效杀伤,其中白细胞介素-4的前导序列与FasL的胞外部分连接。接种表达膜结合FasL的A11小鼠肺癌细胞的小鼠未发生肿瘤,且几乎没有自发肺转移灶。相比之下,注射分泌可溶性FasL的A11细胞的小鼠发生了肿瘤;肿瘤生长及皮下肿瘤的肺转移灶数量与亲本肿瘤无异。通过腹腔注射亲本及表达FasL的A11细胞检测FasL的趋化活性,结果显示分泌可溶性FasL的A11细胞诱导的中性粒细胞迁移水平高于亲本细胞,但不如表达膜结合FasL的A11细胞显著。表达的FasL诱导的抗肿瘤活性似乎与通过Fas/FasL相互作用诱导凋亡的活性相关,而与对中性粒细胞的趋化活性无直接关联。